Expanding Access to Patients in Need Around the World
Interview with Gregg H. Alton, Ph.D., Executive VP, Corporate and Medical Affairs, Gilead Sciences, Inc.
Part 1: Product portfolio and pipeline
on June 20, 2010
(Subtitled in Chinese. Translation by Charles Liu, Ph.D., Gilead Sciences; member of CABS)
At BioPacific2010, Gregg Alton spoke to Essinova host, BeiBei Song about Gilead's HIV/AIDS product portfolio, the company's pipeline status, its global access program and initiatives in Asia.
Tags: CABS, BioPacific 2010, Gregg Alton, Gilead, HIV, AIDS, Viread, Truvada, Atripla, hepatitis C